Endothelial Progenitor Cells and Pulmonary Idiopathic Arterial Hypertension - Tabular View

This Tabular View shows the required WHO registration data elements as marked by ^†

Tracking Information

First Received Date ^†

October 29, 2007

Last Updated Date

October 30, 2007

Start Date ^†

August 2007

Current Primary Outcome Measures ^†

Original Primary Outcome Measures ^†

Change History

Complete list of historical versions of study NCT00551408 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^†

Original Secondary Outcome Measures ^†

Descriptive Information

Brief Title ^†

Endothelial Progenitor Cells and Pulmonary Idiopathic Arterial Hypertension

Official Title ^†

The Determination of Endothelial Progenitor Cells in Pulmonary Idiopathic Arterial Hypertension.

Brief Summary

Endothelial dysfunction ultimately represents an imbalance between the magnitude of injury and the capacity for repair.

Current evidence established that endothelial progenitor cells (EPC) participate in several models of vascular disease as acute coronary syndromes, stroke, diabetes, peripheral artery disease, etc. However EPC in the setting of PAH is less well established. The target of this study is to demonstrate if the number of EPC is increased in a mexican population of patients with PAH.

Detailed Description

Study Phase

Study Type ^†

Observational

Study Design ^†

Case Control, Prospective

Condition ^†

Pulmonary Idiopathic Arterial Hypertension

Intervention ^†

Study Arms / Comparison Groups

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^†

Active, not recruiting

Enrollment ^†

Estimated Completion Date

February 2008

Primary Completion Date

Eligibility Criteria ^†

Inclusion Criteria:

Patients were included in the study if they were in The WHO functional class II to III, and had a mean pulmonary artery pressure >30 mm Hg on right heart catheterization. The ability to walk >50 m during a standardized 6-min walk test.

Exclusion Criteria:

Pulmonary hypertension as a result of heart disease, pulmonary disease, sleep-associated disorders, chronic thromboembolic disease, autoimmune or collagen vascular disease, HIV infection, liver disease, major bleeding requiring blood transfusion,renal dysfunction, and evidence for malignant diseases were excluded.

Gender

Both

Ages

18 Years to 70 Years

Accepts Healthy Volunteers

Contacts ^††

Location Countries ^†

Mexico

Expanded Access Status

Administrative Information

NCT ID ^†

NCT00551408

Responsible Party

Secondary IDs ^††

07-012

Study Sponsor ^†

Unidad de Investigacion Clinica en Medicina S.C.

Collaborators ^††

Investigators ^†

Principal Investigator:

Carlos J Sanchez Diaz, MD.

Unidad de Investigacion Clinica en Medicina SC.

Information Provided By

Unidad de Investigacion Clinica en Medicina S.C.

Verification Date

October 2007

^† Required WHO trial registration data element.
^†† WHO trial registration data element that is required only if it exists.